CARDIFF ONCOLOGY, INC. Deferred Foreign Income Tax Expense (Benefit)
CARDIFF ONCOLOGY, INC. (CRDF) reported Deferred Foreign Income Tax Expense (Benefit) of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-26.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredForeignIncomeTaxExpenseBenefit · last filed 2018-02-26
- CARDIFF ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2017 was $0.00.
- CARDIFF ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2016 was -$114.00K.
- CARDIFF ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2015 was $0.00.
- CARDIFF ONCOLOGY, INC. deferred foreign income tax expense (benefit) for fiscal 2014 was $0.00.
| Period end | Deferred Foreign Income Tax Expense (Benefit) 12 month |
|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-26 |
| 2016-12-31 | -$114.00K 10-K · filed 2018-02-26 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-15 |
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |